Bioxyx (BYX) Reports 100% Viral Clearance in ProLectin-M Phase 2 Trial

Bioxyx (BYX) announced that its ProLectin-M, an investigational HIV-1 pre-exposure prophylaxis (PrEP) candidate, achieved 100% viral clearance in a Phase 2b trial. The trial, which enrolled 120 participants, showed no detectable viral load at the end of treatment. The company said the results support the drug’s potential as a next-generation PrEP therapy. The trial was completed and results were reviewed by an independent data monitoring committee. Bioxyx plans to submit a New Drug Application in the first half of 2026, pending final safety and efficacy data.